000132720 001__ 132720
000132720 005__ 20240303003313.0
000132720 0247_ $$2doi$$a10.1007/s00262-018-2119-y
000132720 0247_ $$2pmid$$apmid:29380009
000132720 0247_ $$2ISSN$$a0340-7004
000132720 0247_ $$2ISSN$$a1432-0851
000132720 0247_ $$2altmetric$$aaltmetric:33826244
000132720 037__ $$aDKFZ-2018-00374
000132720 041__ $$aeng
000132720 082__ $$a610
000132720 1001_ $$0P:(DE-HGF)0$$aKrackhardt, Angela M$$b0$$eFirst author
000132720 245__ $$aClinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach.
000132720 260__ $$aBerlin$$bSpringer$$c2018
000132720 3367_ $$2DRIVER$$aarticle
000132720 3367_ $$2DataCite$$aOutput Types/Journal article
000132720 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659962349_8493$$xReview Article
000132720 3367_ $$2BibTeX$$aARTICLE
000132720 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132720 3367_ $$00$$2EndNote$$aJournal Article
000132720 520__ $$aAdoptive transfer of T cells genetically modified by TCRs or CARs represents a highly attractive novel therapeutic strategy to treat malignant diseases. Various approaches for the development of such gene therapy medicinal products (GTMPs) have been initiated by scientists in recent years. To date, however, the number of clinical trials commenced in Germany and Europe is still low. Several hurdles may contribute to the delay in clinical translation of these therapeutic innovations including the significant complexity of manufacture and non-clinical testing of these novel medicinal products, the limited knowledge about the intricate regulatory requirements of the academic developers as well as limitations of funds for clinical testing. A suitable good manufacturing practice (GMP) environment is a key prerequisite and platform for the development, validation, and manufacture of such cell-based therapies, but may also represent a bottleneck for clinical translation. The German Cancer Consortium (DKTK) and the Paul-Ehrlich-Institut (PEI) have initiated joint efforts of researchers and regulators to facilitate and advance early phase, academia-driven clinical trials. Starting with a workshop held in 2016, stakeholders from academia and regulatory authorities in Germany have entered into continuing discussions on a diversity of scientific, manufacturing, and regulatory aspects, as well as the benefits and risks of clinical application of CAR/TCR-based cell therapies. This review summarizes the current state of discussions of this cooperative approach providing a basis for further policy-making and suitable modification of processes.
000132720 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000132720 588__ $$aDataset connected to CrossRef, PubMed,
000132720 7001_ $$aAnliker, Brigitte$$b1
000132720 7001_ $$0P:(DE-HGF)0$$aHildebrandt, Martin$$b2
000132720 7001_ $$0P:(DE-HGF)0$$aBachmann, Michael$$b3
000132720 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b4$$udkfz
000132720 7001_ $$0P:(DE-He78)a074bc4fb40eed64043b5d34b4d6d523$$aNettelbeck, Dirk$$b5$$udkfz
000132720 7001_ $$aRenner, Matthias$$b6
000132720 7001_ $$0P:(DE-HGF)0$$aUharek, Lutz$$b7
000132720 7001_ $$0P:(DE-He78)bc039c65f54568c14d4aca488c101452$$aWillimsky, Gerald$$b8$$udkfz
000132720 7001_ $$0P:(DE-HGF)0$$aSchmitt, Michael$$b9
000132720 7001_ $$0P:(DE-HGF)0$$aWels, Winfried S$$b10
000132720 7001_ $$aSchüssler-Lenz, Martina$$b11
000132720 773__ $$0PERI:(DE-600)1458489-x$$a10.1007/s00262-018-2119-y$$gVol. 67, no. 4, p. 513 - 523$$n4$$p513 - 523$$tCancer immunology immunotherapy$$v67$$x1432-0851$$y2018
000132720 909CO $$ooai:inrepo02.dkfz.de:132720$$pVDB
000132720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a074bc4fb40eed64043b5d34b4d6d523$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000132720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000132720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bc039c65f54568c14d4aca488c101452$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000132720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000132720 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000132720 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000132720 9141_ $$y2018
000132720 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132720 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132720 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132720 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132720 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER IMMUNOL IMMUN : 2015
000132720 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000132720 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000132720 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132720 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132720 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132720 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132720 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132720 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132720 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132720 9201_ $$0I:(DE-He78)L701-20160331$$kL701$$lDKTK München$$x0
000132720 9201_ $$0I:(DE-He78)G182-20160331$$kG182$$lGMP Einheit  Zelluläre Therapie$$x1
000132720 9201_ $$0I:(DE-He78)L301-20160331$$kL301$$lDKTK Dresden$$x2
000132720 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000132720 9201_ $$0I:(DE-He78)L201-20160331$$kL201$$lDKTK Berlin$$x4
000132720 9201_ $$0I:(DE-He78)L501-20160331$$kL501$$lDKTK Frankfurt$$x5
000132720 980__ $$ajournal
000132720 980__ $$aVDB
000132720 980__ $$aI:(DE-He78)L701-20160331
000132720 980__ $$aI:(DE-He78)G182-20160331
000132720 980__ $$aI:(DE-He78)L301-20160331
000132720 980__ $$aI:(DE-He78)L101-20160331
000132720 980__ $$aI:(DE-He78)L201-20160331
000132720 980__ $$aI:(DE-He78)L501-20160331
000132720 980__ $$aUNRESTRICTED